Ruppiner Kliniken, Neuruppin, Brandenburg, Germany
Anesthesia and intensive care, Unikliniken Ruppin-Brandenburg, Neuruppin, Germany.
BMJ Case Rep. 2022 May 11;15(5):e246770. doi: 10.1136/bcr-2021-246770.
Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford-AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threatening complication called vaccine-induced thrombotic thrombocytopenia (VITT) was reported. As the number of cases increases every day, with the increase in the number of vaccinated people all over the world, this complication is a concern to the medical field. We report a case on the acute management of a patient who presented to us with life-threatening bilateral pulmonary embolism as a complication of VITT after the first dose of vaccination with Oxford-AstraZeneca vaccine against COVID-19.
自使用腺病毒载体疫苗（例如，牛津-阿斯利康疫苗，使用改良的 chimpanzee 腺病毒 ChAdOx1，以及强生疫苗，使用人腺病毒血清型 26）对 COVID-19 病毒感染进行疫苗接种以来，已报告了一种罕见但可能危及生命的并发症，称为疫苗诱导的血栓性血小板减少症（VITT）。随着每天报告病例的增加，以及世界各地接种疫苗人数的增加，这种并发症引起了医学界的关注。我们报告了一例病例，该患者在接种第一剂牛津-阿斯利康 COVID-19 疫苗后，出现了危及生命的双侧肺栓塞并发症，VITT 是其急性管理的病例。
